Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein

Blood (2022) 140 (Supplement 1): 3333–3335.

https://doi.org/10.1182/blood-2022-156564

Published: 2022

Journal Articles

SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models

Liv Johannessen, Susan Henry, Priyanka Sawant, Anthony D'Ippolito, Nan Ke, Ariel Lefkowitz, Matthew Eaton, Wojciech Dworakowski, Maria Rosario, Graeme Hodgson

Blood (2021) 138 (Supplement 1): 1205.

https://doi.org/10.1182/blood-2021-151411

Published: 2021

Journal Articles

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Christopher Fiore, PhD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Kate Madigan, MD, Matthew Eaton, PhD, Graeme Hodgson, PhD, David A. Roth, MD, Qing Kang-Fortner, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137323

Published: 2020

Journal Articles

Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia

Graeme Hodgson, PhD, Liv Johannessen, PhD, Nisha Rajagopal, PhD, Shanhu Hu, PhD, David Orlando, PhD, Matthew Eaton, PhD, Michael McKeown, PhD, Jeffrey W. Tyner, PhD, Stephen E Kurtz, PhD, Kevin Sprott, PhD, Christian Fritz, PhD, Emmanuelle Di Tomaso, PhD

Blood (2017) 130 (Supplement 1): 2651.

https://doi.org/10.1182/blood.V130.Suppl_1.2651.2651

Published: 2017

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Wendy T. Parker, David T. O. Yeung, Alexandra L. Yeoman, Haley K. Altamura, Bronte A. Jamison, Chani R. Field, J. Graeme Hodgson, Stephanie Lustgarten, Victor M. Rivera, Timothy P. Hughes, Susan Branford

Blood (2016) 127 (15): 1870–1880.

https://doi.org/10.1182/blood-2015-09-666214

Published: 2016

Includes: Supplemental data

Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood (2016) 127 (6): 703–712.

https://doi.org/10.1182/blood-2015-08-660977

Published: 2016

Includes: Supplemental data

Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich

Blood (2015) 126 (23): 478.

https://doi.org/10.1182/blood.V126.23.478.478

Published: 2015

Journal Articles

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, David Lawrence, BCS, Andreas Schreiber, PhD, Paul Wang, PhD, Joel Geoghegan, MSc, Stephanie Lustgarten, PhD, Graeme Hodgson, Victor M. Rivera, PhD, Timothy P. Hughes, MD, Hamish Scott, PhD, Susan Branford, PhD

Blood (2014) 124 (21): 399.

https://doi.org/10.1182/blood.V124.21.399.399

Published: 2014

Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera

Blood (2014) 124 (21): 3153.

https://doi.org/10.1182/blood.V124.21.3153.3153

Published: 2014

Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD

Blood (2014) 124 (21): 1783.

https://doi.org/10.1182/blood.V124.21.1783.1783

Published: 2014

Journal Articles

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Haley Altamura, BSc, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Bronte A Jamison, BSc, Chani Field, BSc, Stephanie Lustgarten, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD

Blood (2013) 122 (21): 651.

https://doi.org/10.1182/blood.V122.21.651.651

Published: 2013

Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2013) 122 (21): 652.

https://doi.org/10.1182/blood.V122.21.652.652

Published: 2013

Journal Articles

Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics.

Matthew J. Walter, Rhonda E. Ries, Jon Armstrong, Brian O’Gara, James W. Vardiman, Michael A. Caligiuri, Clara D. Bloomfield, Graeme Hodgson, Joe W. Gray, Richard K. Wilson, Elaine R. Mardis, Timothy J. Ley, members of the Genomics of AML PPG

Blood (2004) 104 (11): 142.

https://doi.org/10.1182/blood.V104.11.142.142

Published: 2004

NARROW

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only